* 4-Antibody AG, of Basel, Switzerland, signed a collaboration agreement with Human Genome Sciences Inc., of Rockville, Md., to discover and develop fully human therapeutic antibodies. Financial terms were not disclosed. The collaboration is focused on 4-Antibody's high-throughput in vitro Retrocyte (Retroviral B lymphocyte) Display technology for rapid discovery of fully human antibodies against targets nominated by HGS.
* BiOasis Technologies Inc., of Vancouver, British Columbia, said its investigational product for cancer, BT21111, delivered Herceptin (trastuzumab, Roche AG) across the blood-brain barrier and into the brain tissue. Fluorescently labeled BT2111 was found in the brain two hours after injection, whereas trastuzumab alone was not found in the brain. The product …
Комментариев нет:
Отправить комментарий